MF

This study tests whether adding navtemadlin to the standard drug ruxolitinib helps people with myelofibrosis who are not getting enough benefit from ruxolitinib alone. About 600 adults with myelofibrosis will first take ruxolitinib, then those with a weak response will be randoml…

This study tests a new drug called flonoltinib maleate in people with intermediate- or high-risk myelofibrosis, a rare bone marrow disorder. The main goal is to see if the drug can shrink the spleen by at least 35% and reduce symptoms like pain and fatigue. About 105 adults aged …

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase tr…

This study tests a new drug called Flonoltinib maleate in about 64 people with intermediate- or high-risk myelofibrosis, a rare bone marrow cancer. Participants must have tried and failed or not tolerated standard JAK inhibitor treatments. The main goal is to see if the drug can …

This study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…